232 related articles for article (PubMed ID: 37982261)
1. Transfusion avoidance in myelodysplastic neoplasms.
Griffiths EA
Curr Opin Hematol; 2024 Mar; 31(2):40-46. PubMed ID: 37982261
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndromes and the role of iron overload.
Harvey RD
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
[TBL] [Abstract][Full Text] [Related]
3. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
4. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
[TBL] [Abstract][Full Text] [Related]
6. Iron overload in patients with myelodysplastic syndromes: An updated overview.
Moukalled NM; El Rassi FA; Temraz SN; Taher AT
Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
[TBL] [Abstract][Full Text] [Related]
7. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
8. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
9. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
10. [Transfusions in myelodysplastic syndromes].
Rose C
Transfus Clin Biol; 2017 Sep; 24(3):209-215. PubMed ID: 28651884
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
12. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
13. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
Valent P; Krieger O; Stauder R; Wimazal F; Nösslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstöcker M
Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
[TBL] [Abstract][Full Text] [Related]
14. Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Finelli C; Parisi S; Paolini S
Expert Rev Hematol; 2022 May; 15(5):411-421. PubMed ID: 35549626
[TBL] [Abstract][Full Text] [Related]
15. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.
An W; Feola M; Levy M; Aluri S; Ruiz-Martinez M; Sridharan A; Fibach E; Zhu X; Verma A; Ginzburg Y
Elife; 2023 Dec; 12():. PubMed ID: 38153418
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
18. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
19. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
20. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]